Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration; electrolytes correct imbalances; low magnesium and calcium adjust levels in renal failure.
Delflex with Dextrose 2.5% is a peritoneal dialysis solution that provides osmotic ultrafiltration and electrolyte replacement. Dextrose creates an osmotic gradient across the peritoneal membrane, promoting fluid removal. The solution corrects electrolyte imbalances and removes metabolic waste products via diffusion and convection.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or 8-10 liters over 10-12 hours for overnight cycler, with dextrose concentration selected based on ultrafiltration needs.
Intraperitoneal administration: 2-3 L per exchange, 4 exchanges per day, with dwell times of 4-6 hours; typical total volume 8-12 L daily.
None Documented
None Documented
Not applicable as a terminal half-life for the solution itself; glucose absorption half-life from peritoneal cavity is approximately 2-4 hours, reflecting peritoneal clearance. There is no systemic accumulation of the solution's components beyond expected glucose metabolism.
2 hours (peritoneal dwell time; systemic absorption minimal; continuous ambulatory peritoneal dialysis (CAPD) exchanges every 4-6 hours maintain steady state)
Primarily eliminated via peritoneal drainage during continuous ambulatory peritoneal dialysis (CAPD). Approximately 60-80% of glucose is absorbed across the peritoneum and metabolized systemically; non-metabolized glucose and other solutes are removed in dialysate effluent. Renal excretion is negligible (<5%) in patients with end-stage renal disease on CAPD.
Renal: 100% (as unchanged drug in urine; no metabolism)
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution